Details for Patent: 9,060,992

Which drugs does patent 9,060,992 protect, and when does it expire?

Patent 9,060,992 protects GATTEX KIT and is included in one NDA.

Protection for GATTEX KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eight patent family members in seven countries.

Summary for Patent: 9,060,992

Title:	Treatment of short bowel syndrome patients with colon-in-continuity
Abstract:	Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
Inventor(s):	Sanguinetti; Elizabeth Lemaire (Salt Lake City, UT), Marriott; Thomas B. (Sandy, UT), Lopansri; Jennifer (Salt Lake City, UT), Blosch; Consuelo Maria (Mercer Island, WA)
Assignee:	NPS Pharmaceuticals, Inc. (Bedminster, NJ)
Application Number:	12/938,117
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,060,992
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,060,992

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	GATTEX KIT	teduglutide recombinant	POWDER;SUBCUTANEOUS	203441-001	Dec 21, 2012		RX	Yes	Yes					Y

International Family Members for US Patent 9,060,992

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2585482
Denmark	1809318
European Patent Office	1809318
Spain	2427150
Hong Kong	1107026
Japan	2008518941